• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Precipio closes Poplar Healthcare OncoMetrix hematopathology division buy

Precipio closes Poplar Healthcare OncoMetrix hematopathology division buy

March 16, 2020 By Sean Whooley

Specialty diagnostics company Precipio (NSDQ:PRPO) announced today that it completed the non-cash acquisition of, among other transactions, the customer base of Poplar hematopathology division called OncoMetrix.

The purchase involves no exchange of cash or equity, so it won’t provide a non-dilutive impact to shareholders, according to a news release. Precipio noted that successful implementation without disproportionate impact from the COVID-19 outbreak will result in revenue growth, gross margin and cash flow.

New Haven, Conn.-based Precipio projects that its revenues will more than double with the hematopathology business increase, while also doing better than double in terms of gross margin and reducing cash burn.

“We are delighted to complete this transaction and partner with Precipio for the hematopathology business, enabling us to focus on our other core businesses”, Poplar CEO James Sweeney said in the news release. “We look forward to continued collaboration with Precipio in other areas of our partnership”.

“While every absorption of a business is challenging, this transaction is an exact fit with current Precipio operations,” added Precipio CEO Ilan Danieli. “We are excited to work with the Oncometrix team and continue to provide their customers and patients with outstanding quality and service. We, too, look forward to a continued fruitful partnership with the Poplar team”.

A previous announcement of the agreement between the companies said that three OncoMetrix sales representatives will transition to Precipio as part of the deal. Precipio also plans to offer Poplar’s solid-tissue pathology services, while Poplar can now offer Precipio’s hematopathology services.

Filed Under: Business/Financial News, Diagnostics, Featured, Mergers & Acquisitions Tagged With: Poplar, precipio

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy